ABBV vs DE: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Deere & Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
AbbVie Inc. · Healthcare
$216.63
+3.8% upside to fair value
Grade C
High Quality
VS
Deere & Company · Industrials
$589.24
-29.6% upside to fair value
Grade D
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+3.8%).
DE trades at a lower forward P/E
(33.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
DE |
| Current Price |
$216.63 |
$589.24 |
| Fair Value Estimate |
$224.76 |
$414.61 |
| Upside to Fair Value |
+3.8%
|
-29.6%
|
| Market Cap |
$382.7B |
$159.1B |
| Forward P/E |
106.2x
|
33.3x
|
| EV / EBITDA |
26.4x
|
18.8x
|
| Price / Sales |
6.1x
|
3.4x
|
| Price / FCF |
18.3x
|
42.2x
|
| Revenue Growth YoY |
+12.4%
|
+6.7%
|
| Gross Margin |
70.7%
|
35.4%
|
| Operating Margin |
27.6%
|
18.4%
|
| Return on Equity |
68.0%
|
18.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.45%
|
2.37%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in pharmaceuticals with a strong focus on immunology, aesthetics, neuroscience, and oncology. The company benefits from a durable competitive moat driven by its immunology franchises, global commercial scale, and R&D capabilities, although it faces challenges from the post-Humira patent cliff and intense competition in biologics and small m…
Deere & Company is a leading global manufacturer of agricultural, construction, and forestry machinery with a durable competitive moat anchored by its number one market share in large agricultural equipment and a dense dealer network. The company benefits from embedded precision agriculture technology that widens its competitive gap, particularly in North America where it holds 40 to 60 percent m…
Accumulation Zones
| Metric |
ABBV |
DE |
| Zone Low |
$168.57 |
$310.96 |
| Zone High |
$191.05 |
$352.42 |
| In Buy Zone? |
No
|
No
|